Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) EBIT: 2013-2024

Historic EBIT for Summit Therapeutics (SMMT) over the last 12 years, with Dec 2024 value amounting to -$226.0 million.

  • Summit Therapeutics' EBIT fell 81.20% to -$65.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$180.7 million, marking a year-over-year decrease of 92.35%. This contributed to the annual value of -$226.0 million for FY2024, which is 62.93% up from last year.
  • According to the latest figures from FY2024, Summit Therapeutics' EBIT is -$226.0 million, which was up 62.93% from -$609.6 million recorded in FY2023.
  • Summit Therapeutics' EBIT's 5-year high stood at -$53.2 million during FY2020, with a 5-year trough of -$609.6 million in FY2023.
  • Over the past 3 years, Summit Therapeutics' median EBIT value was -$226.0 million (recorded in 2024), while the average stood at -$302.6 million.
  • As far as peak fluctuations go, Summit Therapeutics' EBIT tumbled by 745.69% in 2023, and later skyrocketed by 62.93% in 2024.
  • Yearly analysis of 5 years shows Summit Therapeutics' EBIT stood at -$53.2 million in 2020, then slumped by 62.03% to -$86.2 million in 2021, then climbed by 16.36% to -$72.1 million in 2022, then slumped by 745.69% to -$609.6 million in 2023, then surged by 62.93% to -$226.0 million in 2024.